Medivation has bought itself a global license to BioMarin’s talazoparibin in a deal worth $570 million. 

Talazoparibin is a highly-potent, orally-available PARP inhibitor currently in a Phase III study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer.

Under the terms of the deal, Medivation will pay BioMarin $410 million upfront, up to an additional $160 million upon the achievement of regulatory, and sales-based milestones and mid-single digit royalties for the drug, and assumes responsibility for all development for all indications. 

Explaining the strategy behind the move, Hank Fuchs, BioMarin’s chief medical officer, said handing over talazoparib to Medivation “allows us to optimise our portfolio and focus our resources on established areas of expertise - developing novel products to treat rare and ultra-rare genetic diseases”.